Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer

Molecular Therapy

Volumn 10, Issue 6, 2004, Pages 1051-1058

  Lee, Sang Jin ^a,b   Zhang, Yanping ^a   Lee, Sang Don ^a   Jung, Chaeyong ^a   Li, Xiong ^a   Kim, Hong Sup ^a   Bae, Kyung Hee ^a   Jeng, Meei Huey ^a,b   Kao, Chinghai ^a,b   Gardner, Thomas ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b Walther Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; BETA GALACTOSIDASE; E1A PROTEIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; ATTENUATION; CANCER CELL CULTURE; CANCER MORTALITY; CANCER PATIENT; CELL ASSAY; CELL DEATH; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS; DRUG TARGETING; ENHANCER REGION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MORBIDITY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TREATMENT OUTCOME; TUMOR GROWTH; UNITED STATES; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; WESTERN BLOTTING; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CELL LINE, TUMOR; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC; VIRION; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MUS MUSCULUS;

EID: 10344244475     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.08.028     Document Type: Article

References (38)

1. A. Jemal et al. Cancer statistics, 2002 CA Cancer J. Clin. 52 2002 23-47
2. D. MacGrogan R. Bookstein Tumour suppressor genes in prostate cancer Semin. Cancer Biol. 8 1997 11-19
3. P. Koivisto et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res. 57 1997 314-319
4. M.E. Taplin et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N. Engl. J. Med. 332 1995 1393-1398
5. W.D. Tilley et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence Clin. Cancer Res. 2 1996 277-285
6. B.J. Feldman D. Feldman The development of androgen-independent prostate cancer Nat. Rev. Cancer 1 2001 34-45
7. R.F. Gittes Carcinoma of the prostate N. Engl. J. Med. 324 1991 236-245
8. A. Gotoh et al. Development of prostate-specific antigen (PSA) promoter-based gene therapy for androgen-independent (AI) human prostate cancer J. Urol. 160 1998 220-229
9. A. Uchida et al. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: A potential alternative approach to androgen deprivation therapy Urology 58 2 Suppl. 1 2001 132-139
10. P. Sweeney L.L. Pisters Ad5CMVp53 gene therapy for locally advanced prostate cancer-where do we stand? World J. Urol. 18 2000 121-124
11. S.-C. Ko et al. Molecular therapy with recombinant p53 adenovirus in an androgen independent, metastatic human prostate cancer model Hum. Gene Ther. 7 1996 1683-1691
12. G. Cao et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice Cancer Gene Ther. 8 2001 497-505
13. Y. Nasu et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model Gene Ther. 6 1999 338-349
14. D.H. Kirn F. McCormick Replicating viruses as selective cancer therapeutics Mol. Med. Today 2 1996 519-527
15. R. Rodriguez et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res. 57 1997 2559-2563
16. D.C. Yu G.T. Sakamoto D.R. Henderson Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy Cancer Res. 59 1999 1498-1504
17. D.C. Yu et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res. 59 1999 4200-4203
18. G.L. Wright et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 1996 326-334
19. C. Marchal et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia Histol. Histopathol. 19 2004 715-718
20. A. Ghosh W.D. Heston Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell. Biochem. 91 2004 528-539
21. S.L. Su et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression Cancer Res. 55 1995 1441-1443
22. F. Watt et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1 Genomics 73 2001 243-254
23. S.J. Lee et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers Mol. Ther. 6 2002 415-421
24. P.J. Russell et al. A prostate directed gene-directed enzyme prodrug therapy for androgen-sensitive and androgen-independent human prostate cancer 2004
25. R. Alemany C. Balague D.T. Curiel Replicative adenoviruses for cancer therapy Nat. Biotechnol. 18 2000 723-727
26. J. Tan et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells Mol. Endocrinol. 11 1997 450-459
27. S.J. Lee et al. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen J. Mol. Biol. 330 2003 749-760
28. T.G. Huang et al. Telomerase-dependent oncolytic adenovirus for cancer treatment Gene Ther. 10 2003 1241-1247
29. T.D. Chung et al. Characterization of the role of IL-6 in the progression of prostate cancer Prostate 38 1999 199-207
30. C.D. Chen et al. Molecular determinants of resistance to antiandrogen therapy Nat. Med. 10 2004 33-39
31. J.R. Herman et al. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial Hum. Gene Ther. 10 1999 1239-1249
32. J. Maher et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor Nat. Biotechnol. 20 2002 70-75
33. P. Warren et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus Cancer Res. 61 2001 6783-6787
34. E.H. Holmes PSMA specific antibodies and their diagnostic and therapeutic use Expert Opin. Invest. Drugs 10 2001 511-519
35. A.M. Ballangrud et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591) Cancer Res. 61 2001 2008-2014
36. M.R. McDevitt et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer Cancer Res. 60 2000 6095-6100
37. B. Tjoa et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy Prostate 27 1995 63-69
38. J.R. Roubinian et al. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice J. Exp. Med. 147 1978 1568-1583